Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology
Open accessAbstract
Type 2 diabetes mellitus is characterised by beta cell failure, which frequently develops in the setting of insulin resistance. Inflammation contributes to the pathophysiology of type 2 diabetes by impairing insulin action in peripheral tissues and via reduction of beta cell function. Inflammation may also play an important role in the development of complications that arise in patients with type 2 diabetes. Hence, the anti-inflammatory actions of commonly used glucose-lowering drugs may contribute, indirectly, to their mechanisms of action and therapeutic benefit. Herein we highlight the anti-inflammatory actions of glucagon-like peptide-1 (GLP-1), which exerts direct and indirect actions on immune function. The observations that GLP-1 receptor agonists exert anti-inflammatory actions in preclinical studies, taken together with case reports linking improvements in psoriasis with GLP-1 receptor agonist therapy, illustrates the emerging clinical implications of non-classical anti-inflammatory actions of incretin-based therapeutics.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In type 2 diabetes patients, GLP-1 and liraglutide also improve clinical symptoms of psoriasis, a skin inflammatory disease, by downregulation of invariant natural killer T cells.
“In type 2 diabetes patients, GLP-1 and liraglutide also improve clinical symptoms of psoriasis, a skin inflammatory disease, by downregulation of invariant natural killer T cells [31, 113, 114].”
From Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (2016) · cites this paper as [113]
Cites
Type 2 diabetes as an inflammatory disease
Donath, M. Y., & Shoelson, S. E. (2011) · Nature Reviews Immunology · doi:10.1038/nri2925 · Cited by 3,737 · see citing works
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · see citing works
Self-citationDavidovici, B. B., Sattar, N. A., Prinz, J. C., Puig, L., Emery, P., Barker, J. N., van de Kerkhof, P., Ståhle, M., Nestle, F. O., Girolomoni, G., et al. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.103 · Cited by 713 · see citing works
Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
Bullock, B. P., Heller, R. S., & Habener, J. F. (1996) · Endocrinology · doi:10.1210/endo.137.7.8770921 · Cited by 618 · see citing works
Obesity, Waist Circumference, Weight Change, and the Risk of Psoriasis in Women
Setty, A. R. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.15.1670 · Cited by 485 · see citing works
Dipeptidyl Peptidase-4 Inhibition and the Treatment of Type 2 Diabetes
Drucker, D. J. (2007) · Diabetes Care · doi:10.2337/dc07-0228 · Cited by 367 · see citing works
Self-citationGisondi, P., Giglio, M. D., Francesco, V. D., Zamboni, M. M., & Girolomoni, G. (2008) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26427 · Cited by 307 · see citing works
Hogan, A. E., Tobin, A. M., Ahern, T., Corrigan, M. A., Gaoatswe, G., Jackson, R., O’Reilly, V., Lynch, L., Doherty, D. G., Moynagh, P. N., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2232-3 · Cited by 191 · see citing works
Hadjiyanni, I., Siminovitch, K. A., Danska, J. S., & Drucker, D. J. (2010) · Diabetologia · doi:10.1007/s00125-009-1643-x · Cited by 166 · see citing works
Self-citationSkandalis, K., Spirova, M., Gaitanis, G., Tsartsarakis, A., & Bassukas, I. D. (2011) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2011.04062.x · Cited by 158 · see citing works
Peroxisome Proliferator-Activated Receptors (PPARs) and the Human Skin
Sertznig, P., Seifert, M., Tilgen, W., & Reichrath, J. (2008) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200809010-00002 · Cited by 135 · see citing works
Obesity and psoriasis: From the Medical Board of the National Psoriasis Foundation
Bremmer, S. F., Voorhees, A. S. V., Hsu, S., Korman, N. J., Lebwohl, M., Young, M. S., Bebo, B. F., & Blauvelt, A. (2010) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.09.053 · Cited by 130 · see citing works
Libby, P., & Plutzky, J. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.004 · Cited by 127 · see citing works
Exendin-4 modulates diabetes onset in nonobese diabetic mice
Hadjiyanni, I., Baggio, L. L., Poussier, P., & Drucker, D. J. (2008) · Endocrinology · doi:10.1210/en.2007-1137 · Cited by 110 · see citing works
Self-citationBardazzi, F., Balestri, R., Baldi, E., Antonucci, A. M., Tommaso, S. D., & Patrizi, A. (2010) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2009.01281.x · Cited by 105 · see citing works
The role of the low energy diet in psoriasis vulgaris treatment.
Ručević, I., Perl, A., Barišić-Druško, V., & Perl, M. A. (2003) · PubMed · Cited by 82 · see citing works
Zhang, J., Tokui, Y., Yamagata, K., Kozawa, J., Sayama, K., Iwahashi, H., Okita, K., Miuchi, M., Konya, H., Hamaguchi, T., et al. (2007) · Diabetologia · doi:10.1007/s00125-007-0737-6 · Cited by 79 · see citing works
Mittal, R., Malhotra, S., Pandhi, P., Kaur, I., & Dogra, S. (2009) · Archives of Dermatology · doi:10.1001/archdermatol.2009.5 · Cited by 77 · see citing works
A fasting and vegetarian diet treatment trial on chronic inflammatory disorders
Lithell, H., Bruce, A., Gustafsson, I. B., Höglund, N., Karlström, B., LJUNGHALL, K., Sjølin, K., Venge, P., Werner, I., & Vessby, B. (1983) · Acta Dermato Venereologica · doi:10.2340/0001555563397403 · Cited by 76 · see citing works
Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin
List, J. F., He, H., & Habener, J. F. (2006) · Regulatory Peptides · doi:10.1016/j.regpep.2006.02.007 · Cited by 57 · see citing works
Glucagon-like peptide-1(1-37) inhibits chemokine-induced migration of human CD4-positive lymphocytes
Marx, N., Burgmaier, M., Heinz, P., Ostertag, M., Hausauer, A., Bach, H., Durst, R., Hombach, V., & Walcher, D. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0396-5 · Cited by 56 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665 · see citing works
Self-citationAnti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
Lee, Y.-S., & Jun, H.-S. (2016) · Mediators of Inflammation · doi:10.1155/2016/3094642 · Cited by 503 · see citing works
“In type 2 diabetes patients, GLP-1 and liraglutide also improve clinical symptoms of psoriasis, a skin inflammatory disease, by downregulation of invariant natural killer T cells [31, 113, 114].”
BackgroundYusta, B., Baggio, L. L., Koehler, J., Holland, D., Cao, X., Pinnell, L. J., Johnson-Henry, K. C., Yeung, W., Surette, M. G., Bang, K. W. A., et al. (2015) · Diabetes · doi:10.2337/db14-1577 · Cited by 282 · see citing works
Self-citationIncretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls
Drucker, D. J. (2013) · Diabetes · doi:10.2337/db13-0822 · Cited by 272 · see citing works
Self-citationGlucagon-like peptide 1 and appetite
Dailey, M. J., & Moran, T. H. (2013) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.11.008 · Cited by 187 · see citing works
Seufert, J., & Gallwitz, B. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12251 · Cited by 156 · see citing works
Buysschaert, M., Baeck, M., Preumont, V., Marot, L., Hendrickx, E., Belle, A. V., & Dumoutier, L. (2014) · British Journal of Dermatology · doi:10.1111/bjd.12886 · Cited by 104 · see citing works
Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule
Ben Nasr, M., Usuelli, V., Dellepiane, S., Seelam, A. J., Fiorentino, T. V., D’Addio, F., Fiorina, E., Xu, C., Xie, Y., Balasubramanian, H. B., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.05.001 · Cited by 102 · see citing works
Inflammatory Trajectory of Type 2 Diabetes: Novel Opportunities for Early and Late Treatment
Pellegrini, V., Grotta, R. L., Carreras, F., Giuliani, A., Sabbatinelli, J., Olivieri, F., Berra, C., Ceriello, A., & Prattichizzo, F. (2024) · Cells · doi:10.3390/cells13191662 · Cited by 97 · see citing works
Schürmann, C., Linke, A., Engelmann-Pilger, K., Steinmetz, C., Mark, M., Pfeilschifter, J. M., Klein, T., & Frank, S. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.191098 · Cited by 90 · see citing works
Faurschou, A., Gyldenløve, M., Rohde, U., Thyssen, J. P., Zachariae, C. O. C., Skov, L., Knop, F. K., & Vilsbøll, T. (2014) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12629 · Cited by 90 · see citing works
Prattichizzo, F., de Candia, P., & Ceriello, A. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154799 · Cited by 76 · see citing works
Krajewski, P. K., Złotowska, A., & Szepietowski, J. C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216292 · Cited by 69 · see citing works
Deciphering Metabolic Messages From the Gut Drives Therapeutic Innovation: The 2014 Banting Lecture
Drucker, D. J. (2015) · Diabetes · doi:10.2337/db14-1514 · Cited by 68 · see citing works
Self-citationImprovement of psoriasis during exenatide treatment in a patient with diabetes
Buysschaert, M., Tennstedt, D., & Preumont, V. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2011.11.004 · Cited by 57 · see citing works
Kamiya, M., Mizoguchi, F., & Yasuda, S. (2022) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.13025 · Cited by 49 · see citing works
Petković-Dabić, J., Binić, I., Carić, B., Božić, L., Umičević-Šipka, S., Bednarčuk, N., Dabić, S., Šitum, M., Popović‐Pejičić, S., Stojiljković, M. P., et al. (2025) · Biomolecules · doi:10.3390/biom15010046 · Cited by 51 · see citing works
Dynamic Metabolic State of Tissue Resident CD8 T Cells
Konjar, Š., & Veldhoen, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01683 · Cited by 50 · see citing works
Chang, G., Chen, B., & Zhang, L. (2021) · Journal of Dermatological Treatment · doi:10.1080/09546634.2021.1882658 · Cited by 46 · see citing works
Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis
Al-Badri, M. R., & Azar, S. T. (2014) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814543483 · Cited by 44 · see citing works
The effects of GLP‐1RA on inflammatory skin diseases: A comprehensive review
Paschou, I. A., Sali, E., Paschou, S. Α., Ψαλτοπούλου, Θ., Nicolaidou, E., & Stratigos, A. J. (2025) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.20694 · Cited by 50 · see citing works
Cardioprotective anti-hyperglycaemic medications: a review of clinical trials
Ahmed, H. M., Khraishah, H., & Cho, L. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx668 · Cited by 39 · see citing works
GLP-1 Receptor Is Expressed in Human Stomach Mucosa
Broide, E., Bloch, O., Ben-Yehudah, G., Cantrell, D., Shirin, H., & Rapoport, M. J. (2013) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155413497586 · Cited by 33 · see citing works
The pro-healing effect of exendin-4 on wounds produced by abrasion in normoglycemic mice
Bacci, S., Laurino, A., Manni, M. E., Landucci, E., Musilli, C., Siena, G. D., Mocali, A., & Raimondi, L. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.06.056 · Cited by 33 · see citing works
Rameshrad, M., Razavi, B. M., Ferns, G. A. A., & Hosseinzadeh, H. (2019) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-019-00238-7 · Cited by 34 · see citing works
Li, P., Li, K., Yuan, W., Xu, Y., Li, P., Wu, R., Han, J., Yin, Z., Lu, L., & Gao, Y. (2023) · Theranostics · doi:10.7150/thno.84645 · Cited by 28 · see citing works
Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus
Forst, T., & Pfützner, A. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.838559 · Cited by 25 · see citing works
Impact of metabolic status on the incidence of psoriasis: a Korean nationwide cohort study
Kim, E. S., Han, K., Kim, M. K., Park, Y., Baek, K., Moon, S. D., Han, J.-H., Song, K., & Kwon, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-01983-y · Cited by 25 · see citing works
Deng, S., Chen, Z., & Shi, Y. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01486-8 · Cited by 25 · see citing works
The role of incretins and incretin-based drugs in autoimmune diseases
Radbakhsh, S., Atkin, S. L., Simental‐Mendía, L. E., & Sahebkar, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107845 · Cited by 24 · see citing works
Effects of antidiabetic drugs on psoriasis: A meta‐analysis
Chi, C., Lee, C., Liu, C., Wang, S., O'Donnell, F. T., & Tung, T. (2020) · European Journal of Clinical Investigation · doi:10.1111/eci.13377 · Cited by 21 · see citing works
Psoriasis and Vascular Risk: An Update
Katsiki, N., Anagnostis, P. G., Athyros, V. G., Karagiannis, A. I., & Mikhailidis, D. P. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666140417105323 · Cited by 20 · see citing works
Cedirian, S., Donati, M., Rapparini, L., Pampaloni, F., Plaça, M. L., Sgarzani, R., Negosanti, L., Raschi, E., & Starace, M. V. R. (2025) · Dermatology and Therapy · doi:10.1007/s13555-025-01537-5 · Cited by 22 · see citing works
GLP-1 receptor agonists in the treatment of Type 2 diabetes
Åhrén, B. (2013) · Diabetes Management · doi:10.2217/dmt.13.41 · Cited by 16 · see citing works
Jeffrey, L. O. (2019) · Clinical Medical Reviews and Case Reports · doi:10.23937/2378-3656/1410281 · Cited by 17 · see citing works
Medicinal Chemistry of Glucagon-Like Peptide Receptor Agonists
Jones, L. H., & Price, D. A. (2013) · Progress in medicinal chemistry · doi:10.1016/b978-0-444-62652-3.00002-8 · Cited by 15 · see citing works
GLP-1 signaling suppresses menin’s transcriptional block by phosphorylation in β cells
Xing, B., Ma, J., Jiang, Z., Feng, Z., Ling, S., Szigety, K., Su, W., Zhang, L., Jia, R., Sun, Y., et al. (2019) · The Journal of Cell Biology · doi:10.1083/jcb.201805049 · Cited by 15 · see citing works
Molecular mechanisms and drug therapy of metabolism disorders in psoriasis
Liang, Y., Wang, Y., Peng, A., Li, J., & Zhang, K. (2024) · Journal of Dermatological Treatment · doi:10.1080/09546634.2024.2375580 · Cited by 11 · see citing works
Sørum, M. E., Kissow, H., Hartmann, B., Kielsen, K., Sørensen, K., Stinson, S. E., Frithioff‐Bøjsøe, C., Fonvig, C. E., Holm, J., Hansen, T. F., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.793588 · Cited by 11 · see citing works
Incretin therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors
Åhrén, B. (2013) · European Diabetes Nursing · doi:10.1002/edn.221 · Cited by 9 · see citing works
Clinical effects of antidiabetic drugs on psoriasis: The perspective of evidence-based medicine
Zhang, M., Zheng, B.-Y., Chen, H., & Chien, C.-W. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i8.1141 · Cited by 8 · see citing works
Sheth, S., Inestroza, K., Merola, J. F., Weber, B., & Garshick, M. S. (2025) · Journal of Psoriasis and Psoriatic Arthritis · doi:10.1177/24755303251337020 · Cited by 7 · see citing works
Ciancìo, G., Maranini, B., Sandri, G., Amati, G., Bortoluzzi, A., Silvagni, E., Govoni, M., & Giuggioli, D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1744308 · Cited by 7 · see citing works
Oral glucagon-like peptide 1 analogue ameliorates glucose intolerance in db/db mice
Zhang, H., Dong, M., Yuan, S., & Jin, W. (2022) · Biotechnology Letters · doi:10.1007/s10529-022-03288-1 · Cited by 7 · see citing works
Hatwal, A. (2012) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.104049 · Cited by 7 · see citing works
Psoriasis and insulin resistance: a review
Fitzgerald, R., Sadlier, M., Connolly, M., & Tobin, A. (2014) · journal of Diabetes Research and Clinical Metabolism · doi:10.7243/2050-0866-3-3 · Cited by 7 · see citing works
Bouzas, C., Pastor, R., García, S., Monserrat-Mesquida, M., Martínez‐González, M. Á., Salas‐Salvadó, J., Corella, D., Goday, A., Martínez, J. A., Alonso‐Gómez, Á. M., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114561 · Cited by 5 · see citing works
GLP-1RAs in patients with psoriasis
Paschou, I. A., Sali, E., Paschou, S. Α., Ψαλτοπούλου, Θ., Nicolaidou, E., & Stratigos, A. J. (2025) · HORMONES · doi:10.1007/s42000-025-00635-5 · Cited by 5 · see citing works
Basic Concepts in Insulin Resistance and Diabetes Treatment
Bril, F., & Cusi, K. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-72475-1_3 · Cited by 5 · see citing works
Double trouble: psoriasis and cardiometabolic disorders
Mahyoodeen, N. G., Crowther, N. J., & Tikly, M. (2018) · Cardiovascular journal of South Africa/Cardiovascular journal of Southern Africa · doi:10.5830/cvja-2017-055 · Cited by 4 · see citing works
Obesity, Insulin Resistance, and Inflammaging
Itariu, B. K., & Stulnig, T. M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-397803-5.00013-7 · Cited by 4 · see citing works
Sánchez-Feliciano, A., Currier, J. K., Barbieri, J. S., & Charrow, A. P. (2025) · Current Dermatology Reports · doi:10.1007/s13671-025-00481-z · Cited by 2 · see citing works
Cheng, D., Ji, H., Theodosakis, N., Noe, M. H., Chen, S. T., & Sheng‐Kai, K. (2026) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2026.02.008 · Cited by 2 · see citing works
Rosa, J. M. N., Oquendo, B. R., & Lugo, E. D. L. T. (2026) · JAAD Case Reports · doi:10.1016/j.jdcr.2026.02.006 · Cited by 2 · see citing works
Abdelnabi, M. H., Chaisrimaneepan, N., Castillo‐Rodriguez, C., Eshak, N., Sullivan, M. M., Ibrahim, R., Pham, H. N., Farina, J., Ayoub, C., Nagaraja, V., et al. (2025) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-025-01124-z · Cited by 1 · see citing works
Vilarrasa, N., & Pellitero, S. (2025) · Medicina Clínica · doi:10.1016/j.medcli.2025.107184 · Cited by 2 · see citing works
GLP-1-based therapies for obesity: Impact on comorbidities or obesity-related diseases
Vilarrasa, N., & Pellitero, S. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2025.107184 · Cited by 1 · see citing works
Experience with Netakimab and a GLP-1 agonist in patients with psoriasis and metabolic syndrome
Kruglova, L. S., Bridan-Rostovskaya, A. S., & Шатохина, Е. А. (2026) · Medical alphabet · doi:10.33667/2078-5631-2026-3-28-34 · Cited by 1 · see citing works
Where the Future Lies: GLP-1 Receptor Agonists as Therapeutics for Dermatologic Comorbidities
DeCoster, M., & Narla, S. (2026) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2026.09.003 · Cited by 1 · see citing works
Egg Consumption for Appetite Control and Body Weight Regulation
Son, M., Wang, X., & Wu, J. (2019) · Royal Society of Chemistry eBooks · doi:10.1039/9781788013833-00040 · Cited by 1 · see citing works
Psoriasis and insulin resistance
Li, X., Xinran, J., Meng, Y., Li, N., Chunyan, D., Zhengrong, L., & Li, P. (2019) · Huanqiu zhongyiyao · Cited by 1 · see citing works
Teixeira, P. C. C. (2015) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/x485-j713
Stopyra, M., Feret, K., Andrzejczyk, A., Nafalska, N., Tomaszewska, A., Gadzinowska, J., Kokoszka, M., Chodór, M., Szpila, G., & Lewandowska, A. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3970
Where the future lies: GLP-1 receptor agonists as therapeutics for dermatologic comorbidities
DeCoster, M., & Narla, S. (2026) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2026.08.013
Retracted
- Authors
- Drucker, D. J., & Rosen, C. F.
- Affiliations
- Mount Sinai Hospital (CA)
- University Health Network (CA)
- Corresponding author
- Drucker, D. J.
- Venue
- Diabetologia
- Published
- 2011-09-03
- Volume
- 54
- Issue
- 11
- Pages
- 2741-2744
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2068393876
- Cited by
- 66
- References
- 21
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 4 · 2023: 2 · 2022: 2 · 2021: 5 · 2020: 1 · 2019: 7 · 2018: 1 · 2017: 3 · 2016: 2 · 2015: 4 · 2014: 5 · 2013: 10 · 2012: 3
- FWCI
- 4.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Skin Diseases and Diabetes
- Keywords
- GLP-1 receptor agonists, psoriasis, type 2 diabetes, obesity, anti-inflammatory activity, incretin-based therapy, beta-cell failure, insulin resistance, inflammation, immune function, antidiabetic drugs
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Diabetes Mellitus, Type 2, Female, Humans, Male, Psoriasis, Receptors, Glucagon, Glucagon-Like Peptide 1, Natural Killer T-Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
